Reports
The Global Companion Animal Anthelmintics Market was valued at USD 68,293.69 Million in 2024and is anticipated to reach a value of USD 88,548.9 Million by 2032, expanding at a CAGR of 3.3% between 2025 and 2032.
The United States currently dominates the companion animal anthelmintics industry, with a high prevalence of pet ownership and consistent spending on veterinary pharmaceuticals contributing to market strength.
The global companion animal anthelmintics market is witnessing continuous growth, driven by the increasing demand for parasite control in pets. Intestinal worms, heartworms, and other parasitic infections in dogs and cats are driving veterinarians and pet owners toward preventive medications. Rising pet adoption trends in both developed and emerging economies have boosted the consumption of deworming drugs. In 2024, oral formulations remained the most preferred delivery route, accounting for over 52% of total global sales. Additionally, combination therapies that target multiple parasites are gaining attention. Market trends indicate a shift toward palatable, single-dose treatments with improved pharmacokinetics. With growing awareness of zoonotic disease risks, the companion animal anthelmintics industry outlook remains strong, especially in urban regions with dense pet populations. The market forecast reflects expansion in online veterinary pharmacies, contributing to improved accessibility of products globally.
Artificial Intelligence is rapidly transforming the global companion animal anthelmintics market, reshaping everything from diagnosis to treatment strategies. AI-based diagnostic platforms are increasingly being integrated into veterinary settings to identify parasitic infestations with higher precision and speed. These systems reduce the margin of error while analyzing fecal or blood samples, enabling earlier intervention and targeted medication.
Veterinary hospitals and clinics are now leveraging machine learning algorithms to forecast parasite outbreaks regionally, which helps veterinarians recommend deworming schedules based on predictive analytics. With access to real-time patient data, AI-powered platforms are improving treatment outcomes and lowering the risk of drug resistance. The global industry trend now leans toward the integration of AI for supply chain efficiency as well, with automated inventory systems predicting demand spikes for anthelmintics based on historical and seasonal data.
Moreover, AI is also contributing to the formulation stage. Pharma companies are using AI to identify potential active ingredients and improve delivery mechanisms in deworming products, ensuring faster action with minimal side effects. These AI-driven advances are significantly reshaping the companion animal anthelmintics market landscape and supporting sustainable market growth across regions.
“In January 2024, SignalPET, a veterinary AI diagnostics company, launched SignalSTAT, a cutting-edge AI-enabled solution that provides real-time radiology assessments, enabling early detection of internal anomalies such as parasitic infections, and improving treatment precision for companion animals.”
The demand for preventive pharmaceutical solutions is on the rise as pet owners become more proactive about parasite control. With increasing awareness of diseases like giardiasis, heartworm, and hookworm infections, there is a significant uptick in scheduled deworming programs. In 2024, approximately 65% of dog owners in urban areas followed a routine anthelmintic regimen. This proactive approach is fueled by veterinarians recommending monthly or quarterly treatments. The availability of oral, topical, and injectable formulations has made it easier for pet owners to comply with preventive protocols. Additionally, pharmaceutical companies are introducing flavored tablets and chewable formats to boost palatability and adherence. The rise of combination therapies that treat internal and external parasites in one dose is another growth-supporting trend.
Anthelmintic resistance among parasites has emerged as a key barrier in the global companion animal anthelmintics market. The frequent and sometimes improper use of dewormers has led to reduced drug efficacy, particularly in cases involving hookworms and whipworms. In certain U.S. veterinary reports from 2024, over 30% of tested canine samples showed reduced responsiveness to common benzimidazole-based medications. Resistance not only undermines treatment outcomes but also forces veterinarians to adopt costlier or less accessible alternatives. Moreover, the lack of new drug classes entering the market intensifies this issue. As the resistance trend escalates, it could compromise disease control efforts and limit long-term market expansion unless pharmaceutical innovation is accelerated.
The expansion of veterinary telehealth and online retail platforms presents a compelling growth opportunity for the companion animal anthelmintics industry. Telemedicine services are enabling faster consultation and prescription issuance for parasite prevention and treatment. In 2024, nearly 40% of urban pet owners in North America utilized virtual vet consultations, many of which included anthelmintic therapy recommendations. Simultaneously, e-commerce platforms have simplified access to prescription and over-the-counter dewormers, especially in regions with limited veterinary infrastructure. Subscription-based models for monthly treatments and auto-refill options are also gaining popularity. These digital innovations are not only improving treatment adherence but also offering pharmaceutical brands a direct-to-consumer route, supporting broader market penetration and brand loyalty.
One of the most pressing challenges in the companion animal anthelmintics market is ensuring consistent owner compliance with deworming schedules. Despite product availability and veterinarian guidance, many pet owners neglect follow-up doses or discontinue treatment prematurely. A 2024 survey among European pet owners indicated that over 45% skipped at least one scheduled anthelmintic dose in the past year. This inconsistency reduces treatment effectiveness, increases the risk of reinfection, and contributes to the development of resistance. Factors such as forgetfulness, high cost, and misconceptions about parasite risk contribute to poor adherence. Addressing this issue requires a combination of educational campaigns, user-friendly packaging, and digital reminders to improve consistency and optimize health outcomes for companion animals.
• Shift Toward Broad-Spectrum Anthelmintics: Veterinary professionals and pharmaceutical companies are increasingly promoting broad-spectrum anthelmintics that can target multiple types of parasites, including nematodes, cestodes, and trematodes. In 2024, over 60% of newly launched products fell under this category, indicating a clear preference for multi-functional medications. This shift is driven by the convenience of administering a single treatment that addresses a wide parasite load, reducing the need for multiple prescriptions and improving compliance among pet owners.
• Increased Popularity of Chewable and Palatable Formulations: Companion animal owners are showing growing preference for easy-to-administer formats like flavored chewables and dissolvable tablets. Reports indicate that palatable formulations accounted for over 45% of anthelmintics sold in the U.S. in 2024. These innovations are helping address common administration challenges, especially for smaller breeds and finicky eaters. The trend is prompting manufacturers to invest in product palatability trials and consumer-centered R&D.
• Veterinary Clinics Expanding Deworming Awareness Campaigns: Awareness drives initiated by veterinary clinics are playing a vital role in increasing demand. In 2024, several clinics in Europe conducted monthly pet wellness campaigns, resulting in a 27% increase in anthelmintic prescriptions. These campaigns often involve free checkups, parasite screenings, and promotional discounts on deworming products, improving owner awareness and frequency of treatment.
• Rising Adoption of Parasite Diagnostic Kits: Diagnostic accuracy is improving with the growing use of rapid test kits to detect parasite infections before prescribing anthelmintics. In 2024, over 35% of pet clinics in urban Asia integrated point-of-care diagnostic tools for fecal analysis, enhancing treatment precision. This trend is reducing unnecessary drug usage and supporting more targeted, evidence-based anthelmintic therapies, thus elevating the standard of care in the market.
The global companion animal anthelmintics market is segmented by product type, application, and end-user category, each contributing uniquely to the market’s overall performance. The market's diversity stems from the wide range of deworming products tailored to treat different parasite types and species of companion animals. Applications range from routine deworming in home environments to preventive treatments used in veterinary hospitals. Additionally, the end-user landscape includes individual pet owners, veterinary clinics, and animal welfare organizations, all driving varied levels of demand. These segmentation insights are crucial for understanding the growth dynamics and targeting innovations in product development, delivery format, and distribution strategies.
The companion animal anthelmintics market features several product types, including oral anthelmintics, topical anthelmintics, injectable anthelmintics, and combination products. Among these, oral anthelmintics held the largest share in 2024, supported by their ease of use and variety in dosage forms. Flavored chewables and tablets dominate this segment, especially in North America and Europe. Combination products are witnessing the fastest growth due to their ability to treat both internal and external parasites, enhancing convenience and treatment adherence. These products are gaining traction across urban pet populations where monthly prophylactic treatments are common. Topical formulations, while popular for external parasites, are also being used to control internal infections, with growing adoption in Latin America. Injectables, although effective, are primarily used in clinical settings due to the need for professional administration. The rising focus on multi-parasite coverage and user-friendly delivery systems will continue to reshape the product type landscape in the years ahead.
The market finds applications in treatment of roundworms, tapeworms, hookworms, whipworms, and other parasitic infestations in pets. Roundworm treatment leads the segment, with an estimated 40% share in 2024, owing to the high global prevalence of Toxocara canis and Toxocara cati. Regular deworming against roundworms is a priority for most pet owners and veterinary protocols. Hookworm treatment is rapidly growing, especially in the southern regions of the U.S. and parts of Asia, where warm, moist climates increase transmission risks. Tapeworm applications remain stable, mainly addressed via combination therapies. Whipworm treatment shows moderate demand but is limited to certain geographical hotspots. Overall, the diversity of parasite types necessitates broad-spectrum or targeted therapies, which are becoming more customized based on clinical diagnostic results. With emerging technologies for early detection, precision treatment applications are expected to rise, further strengthening the market’s application-specific demand.
The companion animal anthelmintics market is segmented by end-users into individual pet owners, veterinary clinics, animal shelters, and pet hospitals. Individual pet owners represent the largest share, accounting for over 55% of market consumption in 2024. Their purchasing decisions are influenced by veterinarian recommendations, online reviews, and subscription services offering monthly doses. Veterinary clinics are the second-largest end-users, driven by in-clinic treatments, preventive health plans, and awareness campaigns. They are vital in introducing new products to pet owners and ensuring correct administration. Pet hospitals focus on treating more severe or resistant infections and play a key role in administering injectables and specialized treatments. Animal shelters, though limited in budget, rely on bulk or donated anthelmintics to manage large pet populations and prevent outbreaks. The fastest-growing segment is veterinary clinics, owing to the increasing integration of diagnostics, electronic medical records, and bundled parasite management plans, making them a cornerstone of the future growth trajectory in this market.
North America accounted for the largest market share at 41.8% in 2024; however, Asia-Pacific is expected to register the fastest growth, expanding at a CAGR of 4.2% between 2025 and 2032.
The global companion animal anthelmintics market demonstrates varying regional performances. North America led the market due to high veterinary healthcare penetration, widespread awareness about deworming, and an established companion animal sector. In 2024, over 72 million dogs and 60 million cats in the U.S. were under regular veterinary supervision, bolstering the region’s dominance. Meanwhile, the Asia-Pacific market is accelerating due to increasing disposable incomes, booming pet adoption rates in China, India, and Japan, and government-supported animal welfare campaigns. Europe remained stable, supported by advanced healthcare infrastructure, stringent pet welfare regulations, and high awareness about zoonotic diseases. South America and the Middle East & Africa are gradually expanding, driven by the urbanization of pet ownership and growing access to modern veterinary services.
Robust Healthcare Infrastructure and Awareness Fueling Market Penetration
In North America, rising pet ownership and sophisticated veterinary practices drive strong demand for companion animal anthelmintics. As of 2024, more than 68% of U.S. households own pets, and over 55% of them administer anthelmintic treatments annually. Canada also reflects a growing market with increasing sales of oral and topical deworming solutions. Additionally, the U.S. is a hub for innovation in pet pharmaceuticals, offering flavored tablets and spot-on treatments that enhance compliance among pet owners. With top-tier veterinary chains and regulatory support for preventive animal healthcare, the region maintains its leadership in the global landscape.
Consistent Demand Backed by Strict Veterinary Regulations and Pet Insurance
Europe’s companion animal anthelmintics market is characterized by a regulated environment and increasing pet insurance coverage. Countries like Germany, France, and the UK lead in the administration of preventive pet medications. In 2024, Germany alone reported over 20 million dogs and cats receiving routine anthelmintic treatments. The rising popularity of indoor pets and a growing number of veterinary clinics across urban centers further bolster the market. European pet owners are more inclined toward natural and combination therapies, reflecting shifting trends in product demand. Pet insurance penetration, exceeding 40% in countries like Sweden and the UK, is facilitating regular deworming purchases.
Rising Pet Adoption and Urbanization to Accelerate Market Growth
Asia-Pacific is witnessing rapid expansion in the companion animal anthelmintics market. With growing urban middle-class populations, countries like China, India, Japan, and South Korea are experiencing surges in pet ownership. In 2024, pet registration in China reached over 100 million, significantly driving demand for antiparasitic products. Increasing disposable income and awareness about zoonotic risks have led to a 28% year-on-year rise in pet clinic visits in India. E-commerce platforms are also making veterinary medicines, including dewormers, more accessible across rural and suburban regions. This digital shift, coupled with government-backed veterinary outreach, is helping Asia-Pacific emerge as the fastest-growing region.
Gradual Market Expansion Through Veterinary Outreach and Awareness Campaigns
South America is steadily gaining ground in the companion animal anthelmintics industry. Brazil is at the forefront, with over 60% of households owning at least one pet. In 2024, Brazilian veterinary drug imports saw a 12% rise, with antiparasitic drugs forming a major component. The market is further supported by local government initiatives promoting responsible pet ownership and disease prevention. Argentina and Colombia are emerging contributors, witnessing increased availability of anthelmintic drugs in rural vet clinics. Though the market is still developing, growing urbanization and awareness programs are paving the way for stronger regional growth.
Improved Veterinary Access and Pet Care Awareness Encouraging Market Uptake
The Middle East & Africa region is gradually adopting modern veterinary practices, increasing the uptake of companion animal anthelmintics. In 2024, the UAE and Saudi Arabia witnessed rising trends in pet ownership, particularly among urban expatriates. Veterinary clinics in the UAE recorded a 19% increase in deworming service uptake compared to 2023. South Africa, with its growing pet care retail sector, is leading the continent in terms of antiparasitic drug availability. Education campaigns around zoonotic disease risks and cross-border trade in veterinary pharmaceuticals are also contributing to the regional market’s positive trajectory.
United States – 36.2% Market Share in 2024
The U.S. leads globally due to a high pet population, widespread preventive veterinary care, and advanced pharmaceutical infrastructure supporting regular deworming and parasite control.
China – 17.4% Market Share in 2024
China ranks second owing to rapid urbanization, growing pet adoption among millennials, and expanding access to veterinary clinics and e-commerce-based animal health solutions.
The global companion animal anthelmintics industry features a moderately consolidated competitive landscape, with a mix of multinational pharmaceutical giants and regional players competing on innovation, distribution reach, and product diversity. Key players dominate through robust R&D investments and extensive veterinary drug portfolios. In 2024, the top 5 companies accounted for over 60% of the total market share in terms of product volume and veterinary prescriptions. Companies are focusing on broad-spectrum anthelmintics capable of targeting multiple internal and external parasites, which are increasingly preferred by veterinarians and pet owners.
In addition, the growing penetration of e-commerce channels and online veterinary pharmacies is reshaping competition dynamics, particularly in emerging markets such as Brazil, India, and Southeast Asia. The trend toward customized parasite control protocols, supported by data analytics and diagnostics, is intensifying product differentiation strategies. Mergers and acquisitions have become common, with recent deals aiming to expand therapeutic portfolios and strengthen regional market presence, particularly in Asia-Pacific and Latin America.
Zoetis Inc.
Elanco Animal Health
Boehringer Ingelheim Animal Health
Vetoquinol S.A.
Virbac
Ceva Santé Animale
Merck Animal Health
Bayer Animal Health
Dechra Pharmaceuticals PLC
Norbrook Laboratories Ltd.
Technological innovation is reshaping the companion animal anthelmintics market through enhanced drug delivery systems, real-time diagnostic tools, and molecular research. Novel formulations, such as chewable tablets, flavored suspensions, and spot-on treatments, are increasingly being adopted due to better compliance among pets and convenience for pet owners. Smart dosing technology integrated into vet platforms is allowing veterinarians to track parasite control regimens, improving treatment outcomes and driving repeat product sales.
Molecular biology tools are enabling the development of targeted therapies that minimize resistance risk. In 2024, over 35% of newly launched anthelmintic products were developed using recombinant protein or gene-based technologies that focus on parasite-specific mechanisms, thereby improving efficacy. Furthermore, advancements in diagnostic devices are helping vets detect specific worm loads, allowing for tailored deworming protocols and reducing the chances of under- or over-medication.
AI-driven data analytics platforms are also aiding in forecasting parasite outbreaks regionally, enabling preventive treatment strategies. The integration of wearable pet devices and mobile vet apps is further supporting adherence to treatment schedules, especially in urban regions. As more companies invest in precision veterinary care, the role of technology will remain central in shaping product innovation and customer engagement in the coming years.
January 2024 – Zoetis introduced a new chewable anthelmintic tablet in the U.S. designed for monthly administration against roundworms and hookworms in dogs. The launch aimed to address compliance challenges among pet owners by offering improved palatability and simplified dosing.
March 2024 – Elanco Animal Health received regulatory approval in Europe for its extended-spectrum deworming solution for cats and dogs. The formulation covers tapeworms, whipworms, and lungworms, reducing the need for multi-drug combinations.
July 2024 – Virbac expanded its production facility in Brazil, targeting the growing demand for veterinary parasiticides in Latin America. The expansion is expected to increase capacity by 25% and support local distribution.
October 2024 – Ceva Santé Animale launched an AI-powered mobile app that reminds pet owners of deworming schedules and provides region-specific parasite risk alerts. The app witnessed over 100,000 downloads within the first quarter post-launch.
February 2025 – Boehringer Ingelheim announced a partnership with a biotech firm to co-develop mRNA-based anthelmintics targeting gastrointestinal parasites in companion animals, a first-of-its-kind initiative in veterinary pharma innovation.
The global Companion Animal Anthelmintics Market report comprehensively covers all essential aspects shaping the industry, including product innovations, regulatory frameworks, regional demand variations, and emerging technologies. The scope includes an in-depth analysis of various product types such as oral tablets, topical solutions, injectables, and combination therapies used to treat helminth infections in dogs, cats, and other companion animals.
The report also evaluates key applications, such as internal parasite treatment, preventive deworming, and post-operative parasite management, while highlighting different end-user segments, including veterinary clinics, pet hospitals, and home-based treatments. A region-wise outlook is provided, with comparative insights across North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
Additionally, the scope covers market drivers like increased pet adoption, awareness campaigns, and supportive government policies, alongside constraints such as drug resistance and high regulatory compliance costs. The report also details how digital transformation, AI integration, and mobile health tools are influencing product development and delivery models. Overall, the scope aims to offer strategic guidance for stakeholders, including manufacturers, veterinarians, distributors, and investors operating in the evolving companion animal anthelmintics industry.
| Report Attribute/Metric | Report Details |
|---|---|
|
Market Revenue in 2024 |
USD 68293.69 Million |
|
Market Revenue in 2032 |
USD 88548.9 Million |
|
CAGR (2025 - 2032) |
3.3% |
|
Base Year |
2024 |
|
Forecast Period |
2025 - 2032 |
|
Historic Period |
2020 - 2024 |
|
Segments Covered |
By Types
By Application
By End-User
|
|
Key Report Deliverable |
Revenue Forecast, Growth Trends, Market Dynamics, Segmental Overview, Regional and Country-wise Analysis, Competition Landscape |
|
Region Covered |
North America, Europe, Asia-Pacific, South America, Middle East, Africa |
|
Key Players Analyzed |
Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim Animal Health, Vetoquinol S.A., Virbac, Ceva Santé Animale, Merck Animal Health, Bayer Animal Health, Dechra Pharmaceuticals PLC, Norbrook Laboratories Ltd. |
|
Customization & Pricing |
Available on Request (10% Customization is Free) |
